7.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.22
Aprire:
$7.17
Volume 24 ore:
3.35M
Relative Volume:
1.04
Capitalizzazione di mercato:
$1.47B
Reddito:
$331.41M
Utile/perdita netta:
$-226.54M
Rapporto P/E:
-6.2712
EPS:
-1.18
Flusso di cassa netto:
$-97.31M
1 W Prestazione:
+15.44%
1M Prestazione:
-4.39%
6M Prestazione:
-1.20%
1 anno Prestazione:
+61.57%
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Confronta BCRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BCRX
Biocryst Pharmaceuticals Inc
|
7.40 | 1.47B | 331.41M | -226.54M | -97.31M | -1.18 |
![]()
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-25 | Iniziato | Wedbush | Outperform |
2023-11-20 | Ripresa | JP Morgan | Overweight |
2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-02-22 | Aggiornamento | Needham | Hold → Buy |
2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
2021-12-10 | Iniziato | Oppenheimer | Outperform |
2021-08-06 | Downgrade | Jefferies | Buy → Hold |
2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
2021-03-01 | Iniziato | Cowen | Outperform |
2020-09-29 | Ripresa | JP Morgan | Overweight |
2020-06-17 | Iniziato | BTIG Research | Neutral |
2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2018-11-16 | Ripresa | Piper Jaffray | Overweight |
2018-08-08 | Ripresa | JP Morgan | Overweight |
2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2017-12-20 | Iniziato | Barclays | Equal Weight |
2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | Reiterato | FBR Capital | Outperform |
2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Profit Outlook - simplywall.st
BioCryst (BCRX) CFO Resignation Prompts Interim Leadership Change | BCRX Stock News - GuruFocus
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry - TradingView
BioCryst Pharmaceuticals appoints Jon P. Stonehouse as interim CFO - MSN
BioCryst appoints interim CFO following executive departure By Investing.com - Investing.com India
BioCryst Pharmaceuticals CEO Takes On Finance Duties on Interim Basis - MarketScreener
Biocryst Pharmaceuticals Appoints Jon Stonehouse As Interim CFO & Interim Principal Accounting OfficerSEC Filing - marketscreener.com
BioCryst Appoints CEO as Interim CFO Amid Transition - TipRanks
BioCryst appoints interim CFO following executive departure - Investing.com
BioCryst at Needham Conference: Growth Amidst Competition By Investing.com - Investing.com India
BioCryst at Needham Conference: Growth Amidst Competition - Investing.com
(BCRX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Strategic RSU Grants to 10 New Employees: Growth Plans Revealed - Stock Titan
BioCryst to Present at Upcoming Investor Conference - The Manila Times
BioCryst Takes Center Stage: Key Updates Coming at Major Healthcare Conference - Stock Titan
Plasma Protease C1-inhibitor Market Size, Growth Report 2034 - Global Market Insights Inc.
Biocryst discovers new KLK5 inhibitors - BioWorld MedTech
BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews
North Carolina biotech sues to block copies of $400M drug - The Business Journals
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance
Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego
The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St
(BCRX) Technical Data - news.stocktradersdaily.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com
BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada
BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law News
BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView
BioCryst sues to protect ORLADEYO patents - Investing.com India
Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com
Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News
BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com
BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan
BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia
CFO Anthony Doyle resigns at Biocryst - BioCentury
BioCryst CFO resigns, search for successor begins - Investing.com India
BioCryst CFO Anthony Doyle Resigns Effective April 2025 - TipRanks
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):